It	O
was	O
shown	O
by	O
transient	O
expression	O
assay	O
that	O
HS-40	O
behaved	O
as	O
an	O
authentic	O
enhancer	O
for	O
high-level	O
zeta	O
2	O
globin	O
promoter	O
activity	O
in	O
K562	O
cells	O
,	O
an	O
erythroid	O
cell	O
line	O
of	O
embryonic	O
and/or	O
fetal	O
origin	O
.	O

Although	O
sequences	O
located	O
between	O
-559	O
and	O
-88	O
of	O
the	O
zeta	O
2	O
globin	O
gene	O
were	O
dispensable	O
for	O
its	O
expression	O
on	O
enhancerless	O
plasmids	O
,	O
they	O
were	O
required	O
for	O
the	O
HS-40	O
enhancer	O
-mediated	O
activity	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site-directed	O
mutagenesis	O
demonstrated	O
that	O
this	O
HS-40	O
enhancer-	O
zeta	O
2	O
globin	O
promoter	O
interaction	O
is	O
mediated	O
by	O
the	O
two	O
GATA-1	O
factor	O
binding	O
motifs	O
located	O
at	O
-230	O
and	O
-104	O
,	O
respectively	O
.	O

The	O
functional	O
domains	O
of	O
HS-40	O
were	O
also	O
mapped	O
.	O

Bal	O
31	O
deletion	O
mapping	O
data	O
suggested	O
that	O
one	O
GATA-1	O
motif	O
,	O
one	O
GT	O
motif	O
,	O
and	O
two	O
NF-E2/AP1	O
motifs	O
together	O
formed	O
the	O
functional	O
core	O
of	O
HS-40	O
in	O
the	O
erythroid-specific	O
activation	O
of	O
the	O
zeta	O
2	O
globin	O
promoter	O
.	O

Site-directed	O
mutagenesis	O
further	O
demonstrated	O
that	O
the	O
enhancer	O
function	O
of	O
one	O
of	O
the	O
two	O
NF-E2/AP1	O
motifs	O
of	O
HS-40	O
is	O
mediated	O
through	O
its	O
binding	O
to	O
NF-E2	O
but	O
not	O
AP1	O
transcription	O
factor	O
.	O

Finally	O
,	O
we	O
did	O
genomic	O
footprinting	O
of	O
the	O
HS-40	O
enhancer	O
region	O
in	O
K562	O
cells	O
,	O
adult	O
nucleated	O
erythroblasts	O
,	O
and	O
different	O
nonerythroid	O
cells	O
.	O

All	O
sequence	O
motifs	O
within	O
the	O
functional	O
core	O
of	O
HS-40	O
,	O
as	O
mapped	O
by	O
transient	O
expression	O
analysis	O
,	O
appeared	O
to	O
bind	O
a	O
nuclear	O
factor	O
(	O
s	O
)	O
in	O
living	O
K562	O
cells	O
but	O
not	O
in	O
nonerythroid	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
one	O
of	O
the	O
apparently	O
nonfunctional	O
sequence	O
motifs	O
was	O
bound	O
with	O
factors	O
in	O
vivo	O
.	O

In	O
comparison	O
to	O
K562	O
,	O
nucleated	O
erythroblasts	O
from	O
adult	O
human	O
bone	O
marrow	O
exhibited	O
a	O
similar	O
but	O
nonidentical	O
pattern	O
of	O
nuclear	O
factor	O
binding	O
in	O
vivo	O
at	O
the	O
HS-40	O
region	O
.	O

These	O
data	O
suggest	O
that	O
transcriptional	O
activation	O
of	O
human	O
embryonic	O
zeta	O
2	O
globin	O
gene	O
and	O
the	O
fetal/adult	O
alpha	O
globin	O
genes	O
is	O
mediated	O
by	O
erythroid	O
cell-specific	O
and	O
developmental	O
stage-specific	O
nuclear	O
factor-DNA	O
complexes	O
which	O
form	O
at	O
the	O
enhancer	O
(	O
HS-40	O
)	O
and	O
the	O
globin	O
promoters	O
.	O

Transcriptional	O
regulation	O
of	O
the	O
pyruvate	O
kinase	O
erythroid-specific	O
promoter	O
.	O

Mammal	O
pyruvate	O
kinases	O
are	O
encoded	O
by	O
two	O
genes	O
.	O

The	O
L	O
gene	O
produces	O
the	O
erythroid	O
(	O
R-PK	O
)	O
or	O
the	O
hepatic	O
(	O
L-PK	O
)	O
isozymes	O
by	O
the	O
alternative	O
use	O
of	O
two	O
promoters	O
.	O

We	O
report	O
the	O
characterization	O
of	O
the	O
cis-	O
and	O
trans-acting	O
elements	O
involved	O
in	O
the	O
tissue-specific	O
activity	O
of	O
the	O
L	O
gene	O
erythroid	O
promoter	O
.	O

A	O
R-PK	O
DNA	O
fragment	O
extending	O
from	O
-870	O
to	O
+54	O
relative	O
to	O
the	O
cap	O
site	O
confers	O
erythroid	O
specificity	O
to	O
a	O
reporter	O
gene	O
.	O

Within	O
this	O
region	O
,	O
we	O
define	O
a	O
minimal	O
promoter	O
(	O
-62	O
to	O
+54	O
)	O
that	O
displays	O
erythroid-specific	O
activity	O
and	O
contains	O
two	O
DNA	O
binding	O
sites	O
.	O

One	O
,	O
located	O
at	O
-50	O
,	O
binds	O
members	O
of	O
the	O
CCACC/Sp1	O
family	O
and	O
the	O
other	O
,	O
located	O
at	O
-20	O
,	O
binds	O
the	O
erythroid	O
factor	O
GATA-1	O
.	O

Although	O
the	O
-20	O
GATA	O
binding	O
site	O
(	O
AGATAA	O
)	O
is	O
also	O
a	O
potential	O
TFIID	O
binding	O
site	O
,	O
it	O
does	O
not	O
bind	O
TFIID	O
.	O

Furthermore	O
,	O
the	O
substitution	O
of	O
this	O
GATA	O
binding	O
site	O
by	O
a	O
canonical	O
TFIID	O
binding	O
site	O
suppresses	O
the	O
promoter	O
activity	O
.	O

Mutations	O
and	O
deletions	O
of	O
both	O
sites	O
indicate	O
that	O
only	O
the	O
association	O
of	O
CCACC/Sp1	O
and	O
GATA	O
binding	O
sites	O
can	O
drive	O
efficient	O
and	O
tissue-specific	O
expression	O
of	O
this	O
R-PK	O
minimal	O
promoter	O
.	O

Finally	O
,	O
by	O
co-transfection	O
experiments	O
,	O
we	O
study	O
the	O
elements	O
involved	O
in	O
the	O
hGATA-1	O
transactivation	O
of	O
the	O
R-PK	O
promoter	O
in	O
HeLa	O
cells	O
.	O

Protease	O
treatment	O
of	O
nuclear	O
extracts	O
distinguishes	O
between	O
class	O
II	O
MHC	O
X1	O
box	O
DNA-binding	O
proteins	O
in	O
wild-type	O
and	O
class	O
II-deficient	O
B	O
cells	O
.	O

The	O
X	O
box	O
region	O
is	O
critical	O
for	O
directing	O
the	O
expression	O
of	O
class	O
II	O
major	O
histocompatibility	O
complex	O
genes	O
in	O
B	O
lymphocytes	O
.	O

Although	O
several	O
class	O
II	O
promoter-specific	O
DNA	O
binding	O
factors	O
have	O
been	O
described	O
,	O
only	O
the	O
X	O
box	O
region	O
factor	O
,	O
RFX	O
,	O
shows	O
a	O
genetic	O
correlation	O
with	O
class	O
II	O
expression	O
,	O
being	O
deficient	O
in	O
some	O
B	O
cell	O
lines	O
derived	O
from	O
patients	O
with	O
class	O
II-deficient	O
congenital	O
immunodeficiency	O
.	O

To	O
further	O
evaluate	O
the	O
role	O
of	O
X	O
box	O
DNA-binding	O
proteins	O
in	O
class	O
II	O
gene	O
expression	O
,	O
the	O
role	O
of	O
the	O
X	O
box	O
region	O
was	O
examined	O
in	O
both	O
class	O
II-positive	O
and	O
-negative	O
lymphoid	O
cells	O
.	O

In	O
addition	O
to	O
the	O
wild-type	O
B	O
cell	O
line	O
Raji	O
,	O
two	O
class	O
II	O
transcriptional	O
mutant	O
cell	O
lines	O
,	O
SJO	O
and	O
RJ2.2.5	O
,	O
and	O
Jurkat	O
,	O
a	O
class	O
II	O
negative	O
T	O
cell	O
line	O
,	O
were	O
examined	O
.	O

In	O
contrast	O
to	O
wild-type	O
B	O
cells	O
,	O
neither	O
of	O
the	O
class	O
II	O
mutant	O
cell	O
lines	O
could	O
use	O
the	O
X	O
box	O
region	O
to	O
direct	O
the	O
expression	O
of	O
a	O
transiently	O
transfected	O
reporter	O
gene	O
,	O
indicating	O
that	O
the	O
X	O
box-dependent	O
transcriptional	O
pathway	O
is	O
defective	O
in	O
these	O
cells	O
.	O

The	O
binding	O
activity	O
of	O
the	O
X1	O
box	O
DNA-binding	O
protein	O
RFX	O
was	O
examined	O
and	O
found	O
to	O
be	O
present	O
in	O
wild-type	O
B	O
cells	O
and	O
the	O
mutant	O
RJ2.2.5	O
but	O
was	O
absent	O
in	O
SJO	O
and	O
Jurkat	O
.	O

However	O
,	O
other	O
X1	O
box-specific	O
activities	O
were	O
detected	O
in	O
all	O
these	O
cell	O
lines	O
.	O

To	O
determine	O
whether	O
these	O
different	O
X1	O
box	O
activities	O
represented	O
distinct	O
DNA	O
binding	O
proteins	O
or	O
multimeric	O
forms	O
of	O
the	O
same	O
factor	O
(	O
s	O
)	O
,	O
protease	O
treatment	O
of	O
the	O
crude	O
nuclear	O
extracts	O
followed	O
by	O
DNA-binding	O
assays	O
were	O
carried	O
out	O
and	O
demonstrated	O
that	O
B	O
cell	O
extracts	O
contain	O
at	O
least	O
two	O
X1-specific	O
factors	O
.	O

One	O
of	O
these	O
cleaved	O
products	O
(	O
band	O
1	O
pk	O
)	O
correlates	O
with	O
RFX	O
activity	O
.	O

A	O
similar	O
comparison	O
with	O
protease-treated	O
extracts	O
prepared	O
from	O
Jurkat	O
cells	O
demonstrated	O
the	O
presence	O
of	O
the	O
band	O
1pk	O
activity	O
despite	O
an	O
absence	O
of	O
the	O
native	O
RFX	O
activity	O
.	O

In	O
contrast	O
,	O
protease	O
treatment	O
and	O
analysis	O
of	O
SJO	O
extracts	O
showed	O
no	O
detectable	O
levels	O
of	O
the	O
band	O
1pk	O
activity	O
.	O

These	O
results	O
demonstrate	O
that	O
multiple	O
X1	O
box-specific	O
DNA-binding	O
activities	O
exist	O
in	O
all	O
lymphoid	O
cells	O
,	O
but	O
the	O
presence	O
of	O
an	O
actively	O
binding	O
RFX	O
species	O
correlates	O
with	O
class	O
II	O
transcription	O
.	O

Human	O
immunodeficiency	O
viruses	O
containing	O
heterologous	O
enhancer/promoters	O
are	O
replication	O
competent	O
and	O
exhibit	O
different	O
lymphocyte	O
tropisms	O
.	O

